Saturday, 31 October 2026European Markets

AUSTEVOLL SEAFOOD And SALMAR Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - AUSTEVOLL SEAFOOD (AUSS.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
AUSTEVOLL SEAFOOD (AUSS.OL) kr85.65 7.18% 15.89%
SALMAR (SALM.OL) kr583.50 6.02% 7.71%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. AUSTEVOLL SEAFOOD (AUSS.OL)

7.18% Forward Dividend Yield and 15.89% Return On Equity

Austevoll Seafood ASA, a seafood company, engages in the production of salmon and trout, white fish, and pelagic in Norway, the European Union, the United Kingdom, Eastern Europe, Africa, North America, Asia, and South America. The company is involved in the ownership and operation of fishing vessels; and sale and distribution of different fish species and processed fish products. It also produces white fish products, fish meals, and fish oils; omega-3 oil; and canned and frozen fish products. The company was incorporated in 1981 and is headquartered in Storebø, Norway. Austevoll Seafood ASA is a subsidiary of Laco AS.

Earnings Per Share

As for profitability, AUSTEVOLL SEAFOOD has a trailing twelve months EPS of kr0.15.

PE Ratio

AUSTEVOLL SEAFOOD has a trailing twelve months price to earnings ratio of 571. Meaning, the purchaser of the share is investing kr571 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.89%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on May 26, 2023, the estimated forward annual dividend rate is 5.5 and the estimated forward annual dividend yield is 7.18%.

Growth Estimates Quarters

The company's growth estimates for the present quarter is 230.3% and a drop 13.7% for the next.

Moving Average

AUSTEVOLL SEAFOOD's worth is way above its 50-day moving average of kr74.99 and under its 200-day moving average of kr85.76.

Revenue Growth

Year-on-year quarterly revenue growth grew by 21.9%, now sitting on 32.61B for the twelve trailing months.

More news about AUSTEVOLL SEAFOOD.

2. SALMAR (SALM.OL)

6.02% Forward Dividend Yield and 7.71% Return On Equity

SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming Central Norway, Fish Farming Northern Norway, Icelandic Salmon, Sales & Industry, and SalMar Aker Ocean segments. It is involved in the broodstock, harvesting, processing, and smolt production activities. In addition, the company offers fish fillets and related products. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.

Earnings Per Share

As for profitability, SALMAR has a trailing twelve months EPS of kr13.18.

PE Ratio

SALMAR has a trailing twelve months price to earnings ratio of 44.27. Meaning, the purchaser of the share is investing kr44.27 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.71%.

Sales Growth

SALMAR's sales growth is 0.6% for the present quarter and 10.5% for the next.

More news about SALMAR.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com